---
title: PPWR Material Minimisation and Design for Recycling in Pharma Packaging: A Roadmap for Early Brand Redesign
lang: en
source: https://mindsprt.dev/en/knowledge/research-ppwr-pharma-packaging-redesign-taiwan-brands/
---

# PPWR Material Minimisation and Design for Recycling in Pharma Packaging: A Roadmap for Early Brand Redesign

*In-Depth Research · 16 min read · 2026-08-26*

> Focusing on material minimisation and design for recycling (DfR) requirements under the EU Packaging and Packaging Waste Regulation (PPWR), this paper examines how export-driven brand owners and packaging designers can redesign during early new product development (NPD). Using a structured literature synthesis, it combines PPWR policy commentary, packaging data governance frameworks, South Korean sustainable packaging ecosystem research, and redesign audit methodologies alongside direct industry reporting. The analysis shows that pharmaceutical packaging compliance requires reallocating functions across packaging layers and embedding interoperable material data upstream

**Quick answer:** Focusing on material minimisation and design for recycling (DfR) requirements under the EU Packaging and Packaging Waste Regulation (PPWR), this paper explores how export-oriented brand owners and packaging designers can execute redesigns during the early stages of new product development

## 1. Introduction: Why Pharma Packaging Is PPWR's Toughest Test Case

The EU Packaging and Packaging Waste Regulation (PPWR, Regulation (EU) 2025/40) turns material minimisation and design for recycling (DfR) from voluntary initiatives into mandatory market access requirements. Pharma packaging is among the hardest categories to adapt because of strict statutory labelling and protective requirements. Industry reports indicate that PPWR is pushing pharmaceutical packaging toward simpler, recyclable structural designs [1]. This shift directly affects Asian export and OEM supply chains, where European brand owners specify packaging requirements while Asian converters and printers execute the structure and printing.

Academic discussions reflect the same urgency. Research on building sustainable packaging ecosystems under PPWR shows that EU regulations are driving systemic industry-level restructuring rather than piecemeal corporate fixes [3]. Under a governance framework where Extended Producer Responsibility (EPR) runs alongside PPWR, packaging data interoperability is the foundation for governing material flows [2]. Industry positions are not fully aligned. Plastics industry groups have submitted comments on the Commission's PPWR proposal, revealing tension between regulatory feasibility and environmental goals [4].

Current discussions leave three major gaps:

・First, most studies focus on general packaging categories. There is a lack of dedicated analysis on how pharmaceutical regulatory constraints (such as package inserts, anti-counterfeiting serialization, and child-resistant closures) interact with PPWR material minimisation rules.

・Second, the packaging redesign methodology literature centers mainly on environmental audits and checklists, offering little guidance on embedding these tools into early New Product Development (NPD) schedules.

・Third, existing literature focuses on Europe and South Korea, offering limited operational insight for supply chains in regions like Taiwan that act as specification receivers.

This paper makes three contributions, each corresponding to a subsequent section:

・First, mapping the issue clusters and divergences between PPWR pharma packaging rules and existing sustainable packaging research to pinpoint research gaps (Section 2).

・Second, breaking down the two structural constraints on pharma packaging material reduction, namely the dual squeeze on design freedom and non-interoperable material flow data, showing why early intervention is the only low-cost window (Sections 3 and 4).

・Third, translating the analysis into actionable, three-tier workflows for Taiwan's small and medium printers, designers, and brand owners, detailing processes, costs, and timelines (Section 5).

## 2. Literature and Current State Review: Three Parallel, Unconverged Research Tracks

Existing discussions fall into three main clusters operating at different levels of inquiry, with little intersection. This section reviews each cluster before narrowing down to our focus.

Cluster 1: Regulatory Response and Industry Ecosystems. Studies on sustainable packaging ecosystems under PPWR treat EU regulations as external drivers of industrial restructuring, arguing that the response must be cross-enterprise ecosystem collaboration rather than isolated tweaks [3]. This approach captures systemic regulatory pressure well, but stays at the macro-industry level without addressing category-specific design constraints. Unlike those studies, this paper narrows the unit of analysis down to pharmaceutical packaging, a distinct category bound by statutory labelling duties, tackling the internal category conflicts that ecosystem research overlooks.

Cluster 2: Data Governance and Material Flow Interoperability. Under co-existing EPR and PPWR governance, interoperable packaging data frameworks serve as the foundation for material flow management [2]. This perspective contributes a valuable insight: compliance is an information challenge, not just a physical design problem. If upstream and downstream partners describe a package's material composition inconsistently, recyclability claims cannot be verified. This paper builds on that premise, arguing that data disconnects are especially severe across pharmaceutical supply chains because drug registration changes prevent packaging data updates from syncing with standard consumer goods cycles.

Cluster 3: Packaging Redesign Methodologies. The methodology literature offers two toolsets. The first consists of checklist-based packaging planning tools that break packaging decisions into item-by-item verification points [5]. The second involves redesign methods grounded in environmental audits, using case studies to show how auditing existing packaging systems reveals directions for improvement [6]. Both toolsets share a common limitation: they assume an existing packaging system as the audit subject, making them post-hoc interventions. This paper differs by arguing that under PPWR, effective intervention must shift to early NPD, because modifying pharma packaging after drug registration incurs far higher costs than consumer goods.

Cluster 4: Divergent Industry Positions. Materials sector feedback on PPWR proposals reflects a lack of consensus among stakeholders regarding feasibility [4]. In practice for supply chains, this divergence means regulatory details may still shift during rollout. Design decisions must therefore retain flexibility rather than locking into a single material assumption.

In summary, current literature captures regulatory pressure (Cluster 1), data infrastructure (Cluster 2), redesign methods (Cluster 3), and stakeholder divergence (Cluster 4), yet lacks an early-intervention path linking all four specifically for pharmaceutical packaging. That is where this study steps in.

## 3. Structural Constraint 1: The Dual Squeeze on Pharma Packaging Design Freedom

The core difficulty in pharma packaging material reduction lies in design freedom being squeezed simultaneously by PPWR environmental targets and drug regulatory functional requirements. These two priorities do not always align. This section explains how this dual constraint works.

PPWR pushes pharma packaging toward simpler, recyclable structures [1]. From a material reduction perspective, the most direct approach is eliminating outer cartons, shedding packaging layers, and adopting mono-material structures. Yet every layer in pharma packaging serves a dedicated function. The outer carton carries statutory package inserts and serialized anti-counterfeiting codes, the aluminum-plastic blister provides moisture and oxygen barrier protection along with unit-dose dispensing, and the inner tray protects against transit shocks. As a result, pharma packaging cannot simply drop a layer like general consumer goods. It requires reallocating functions before any physical layer can be removed.

Take mono-materials as an example. Design for recycling generally favors minimizing material types, whereas aluminum-plastic composite blisters are classic multi-material structures that are difficult to recycle. Switching to an all-plastic or all-paper structure changes barrier performance and drug stability profiles, which in turn triggers regulatory drug registration variations. This explains why recyclability updates in pharma packaging consistently lag behind food and cosmetics: the regulatory cost and timeline hurdles are far harder to overcome than the technical hurdles.

This dual squeeze also alters how methodological tools apply. Existing environmental audit redesign methods evaluate current packaging systems to find improvement opportunities [6]. In pharma contexts, that audit must record the statutory function of each layer, or material reduction proposals will be rejected during regulatory review. In other words, audit checklists need a dedicated regulatory function field. We view this as a necessary extension of existing methods for the pharma category, not a replacement.

## 4. Structural Constraint 2: Non-Interoperable Material Flow Data and the Early Intervention Window

The second structural constraint sits at the data level: recyclability claims require verifiable material composition data, yet current supply chain data formats are not interoperable. This section explains how this bottleneck dictates the timing of redesign intervention.

Under parallel EPR and PPWR governance, an interoperable packaging data structure is the necessary foundation for managing material flows [2]. The practical implication is clear: if brand owners cannot declare packaging material composition, weight, and recyclability classifications in a standardized format downstream, compliance claims will fail even if the physical design meets standards. This means Taiwanese printers and converters must deliver structured material data alongside quotes and physical samples.

Data bottlenecks and timeline constraints compound each other. Checklist methods for packaging planning break decisions into verifiable items [5], implicitly assuming clear answers exist at decision time. In pharma NPD workflows, once material and structural choices enter stability testing and drug filing stages, they are effectively locked. Backfilling data or altering structures at that point drives costs up sharply. The effective window for intervention sits strictly between formula and dosage finalization and the start of stability testing.

From an ecosystem perspective, capturing this window requires cross-company collaboration. Sustainable packaging ecosystem research shows that responding to PPWR requires systemic action rather than scattered efforts by individual firms [3]. Extending this view to pharma packaging, systemic collaboration means packaging suppliers must participate in early NPD as technical partners, shifting their role upstream to deepen cooperation.

Finally, regulatory uncertainty remains. Materials industry feedback on PPWR proposals highlights split opinions on feasibility [4]. While uncertainty should not excuse delay, it shapes design strategy: early redesign must establish a portfolio of interchangeable material options rather than locking into a single track.

## 5. Implications for Taiwan's Design and Printing Industry: A Three-Tier Action Path

This section translates the analysis into operational recommendations across three tiers. Taiwan's pharma packaging supply chain consists primarily of small and medium printers and converters, with design services mostly outsourced and brand owners frequently acting as specification receivers for OEM clients. Each tier holds different levers of intervention.

Small and Medium Printing Plants. The operational priority is building the capability to deliver material data.

・Establish material composition records for every part number, recording layer breakdown, material type, basis weight (gsm), coating, and varnish types in structured fields matching the reporting formats required by data interoperability frameworks [2].

・Include mono-material options in standard quotations alongside current composite structures, enabling brand owners to compare choices directly during initial quoting.

・Generate weight delta data during sample proofing, before and after material reduction, providing brand owners with raw evidence for compliance filings.

The incremental costs for these three tasks stem mainly from upfront data setup and added sample weighing steps. Because no new machinery is required, most small and medium plants can readily absorb them.

Designers. The operational priority is shifting compliance checks into the conceptual design phase.

・Tag the functional attribution of every structural element during initial concepts, distinguishing statutory essentials (inserts, serialization, child-resistant opening) from marketing options.

・Combine existing environmental audit redesign methods [6] with packaging planning checklists [5], adding the regulatory function field described in Section 3.

・Offer alternatives at the pitch stage for surface finishes that disrupt recycling sortation (such as UV varnishing, foil stamping, and film lamination) to avoid redesigning from scratch later.

Our analysis views designers here as constraint translators who convert regulatory rules into structural decisions. This capability is not yet widely priced in Taiwan's design services market and offers a clear path to professional differentiation.

Brand Owners. The operational priority is changing supplier onboarding timing and internal milestone scheduling.

・Bring packaging suppliers on board right after formula and dosage form finalization and before stability testing begins. As shown in Section 4, this is the lowest-cost window for modifications.

・Run parallel evaluations of material options within this window, keeping at least two interchangeable options ready to handle future adjustments in regulatory details [4].

・Create an internal master packaging data record, ensuring the same packaging specification is described consistently across customs declarations, EPR filings, and client audits [2].

Our analysis indicates that the third step is critical for export-oriented brands, because resolving compliance disputes caused by inconsistent data often costs more than the packaging redesign itself.

## 6. Conclusion and Limitations

This study addresses how brand owners should execute early redesigns under PPWR requirements for pharma packaging material reduction and recyclability. The analysis yields three conclusions:

・First, the bottleneck in pharma packaging material reduction is not material technology, but the dual constraint on design freedom from environmental rules and drug regulations. Material reduction requires reallocating functions before physical layers can be removed.

・Second, proving recyclability compliance depends on interoperable material flow data [2], expanding what printers and converters deliver from physical samples to structured data sets.

・Third, the effective intervention window opens after formula finalization and closes before stability testing starts. Missing this window causes change costs to spike.

This study acknowledges two specific limitations. The first involves data coverage: available empirical literature focuses on packaging data architectures [2], Korean ecosystem construction [3], materials sector positions [4], and general redesign methods [5][6], with no quantitative empirical studies evaluating pharma packaging material reduction outcomes. The deductions in Sections 3 and 4 regarding pharma-specific traits are mechanism-based analyses rather than empirically tested results. The second limitation concerns extrapolation boundaries: the referenced methodology papers date from 2000 [5] and 2014 [6], formulated under regulatory frameworks that predated mandatory PPWR requirements. Their application here is limited to their structured auditing logic without adopting their original weighting metrics.

Future research can advance along two lines. The first is building a layer-by-layer functional mapping dataset for pharma packaging, documenting statutory functions and substitution potential for each structural layer to quantify reduction assessments. The second is conducting empirical surveys on supplier onboarding timing among Taiwanese export pharma manufacturers, testing whether the pre-stability testing window hypothesis holds in real-world NPD schedules and measuring the actual impact of early onboarding on change costs.

## Key Takeaways

The bottleneck in pharma packaging material reduction is not material technology, but the fact that every layer carries statutory duties. Functions must be reallocated before any physical layer can be eliminated.

With PPWR running alongside EPR, recyclability claims require interoperable material flow data. What printers and converters deliver is expanding from physical samples to structured material data.

The lowest-cost redesign window sits between formula and dosage finalization and the start of stability testing. Once drug filing begins, designs are locked.

Incremental investments for small and medium printers center on data building and sample weighing, representing procedural additions rather than machinery purchases.

Stakeholders still disagree on regulatory specifics. Early design must maintain at least two interchangeable material paths to avoid getting locked into a single assumption.

## Further Perspectives

PPWR expands the definition of manufacturing deliverables in printing, with clients demanding auditable material data for third-party verification. Small and medium shops have long kept data scattered across paper quotes and shop floor experience. Building systematic data handling capabilities now becomes a fresh bargaining chip to win contracts. For designers, professionals who can translate regulatory rules into structural decisions are scarce in the current market, and that skill deserves dedicated billing. The entry point for AI and SaaS is distinct: structured material composition tracking, initial recyclability screening, and automated weight delta calculations are rule-based, repetitive tasks well suited for software tools rather than manual maintenance. Two open challenges remain: first, recyclability assessment standards are not yet unified across recycling systems, so tooling can produce conclusions that seem precise but lack portability; second, the pharma sector lacks open layer-by-layer functional benchmarks, meaning any automated assessment still needs manual review and cannot be fully automated anytime soon.

## References

[1] [PPWR Mandates Material Reduction and Recyclability for Pharma Packaging: How Brands Can Redesign Early](https://www.packaginginsights.com/news/ppwr-pharma-packaging-redesign.html)

[2] Singh J. (2026). [An interoperable packaging data architecture for material flow governance under EPR and PPWR](https://doi.org/10.2139/ssrn.6695749). DOI: 10.2139/ssrn.6695749

[3] Korea Sustainable Packaging Forum Committee, Kim M., Kim J. (2026). [A Study on Building a Sustainable Packaging Ecosystem in Response to the EU PPWR Regulation](https://doi.org/10.20909/kopast.2026.32.1.7). KOREAN JOURNAL OF PACKAGING SCIENCE AND TECHNOLOGY. DOI: 10.20909/kopast.2026.32.1.7

[4] [Plastics Europe comments on the European Commission’s Packaging and Packaging Waste Regulation (PPWR) proposal](https://doi.org/10.12968/s0306-3747%2823%2970013-4). Additives for Polymers. DOI: 10.12968/s0306-3747(23)70013-4

[5] International Trade Centre (2000). [Packaging planner’s checklist](https://doi.org/10.18356/cf3015b3-en). DOI: 10.18356/cf3015b3-en

[6] Matthews J., Parr C., Araoye O. et al. (2014). [Environmental Auditing of a Packaging System for Redesign: A Case Study Exploration](https://doi.org/10.7763/jocet.2014.v2.138). Journal of Clean Energy Technologies. DOI: 10.7763/jocet.2014.v2.138

## FAQ

### What are PPWR's main requirements for pharmaceutical packaging?

PPWR pushes pharma packaging toward simpler, recyclable structures, focusing on material minimisation and design for recycling (DfR). For brands and supply chains exporting to the EU, this shifts from a voluntary initiative into a mandatory market access condition.

### Why is reducing materials harder in pharma packaging than in food or cosmetics?

Because each layer of pharma packaging usually performs statutory functions, such as outer cartons carrying package inserts and serialized anti-counterfeiting codes, or blisters providing barrier protection and unit dosing. Functions must be reallocated before eliminating any layer, and structural changes can trigger drug registration variations.

### What is the latest stage for brand owners to launch packaging redesigns?

The lowest-cost window sits after formula and dosage form finalization and before stability testing begins. Once projects enter stability testing and drug filing, material and structural decisions are effectively locked, and later revisions face a completely different cost structure.

### Do small and medium printing plants need new machinery to comply?

In most cases, no. Incremental investments focus on building one-time material composition records and adding weight measurement steps during sample proofing, which are process adjustments rather than machinery purchases.

### Are existing packaging environmental audit methods still applicable?

Their structured auditing logic remains valid, but when applied to pharmaceuticals, audits must include a regulatory function field documenting the statutory role of each structural layer. Otherwise, material reduction proposals derived from the audit risk rejection during regulatory drug review.


---

> HTML version: https://mindsprt.dev/en/knowledge/research-ppwr-pharma-packaging-redesign-taiwan-brands/
> MINDS — 麥思印刷整合有限公司 · https://mindsprt.dev